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Abstract
Extracellular ATP is known to mediate synaptic transmission as a neurotransmitter or a
neuromodulator via ionotropic P2X and metabotropic P2Y receptors. Several lines of evidence
have suggested that ATP facilitates pain transmission at peripheral and spinal sites via the P2X
receptors, in which the P2X3 subtype is considered as an important candidate for the effect.
Conversely, we previously found that the activation of supraspinal P2X receptors evoked
antinociception. However, the subtypes responsible for the antinociception via supraspinal P2X
receptors remain unclear. In the present study, we showed that intracerebroventricular (i.c.v.)
pretreatment with A-317491 (1 nmol), the novel non-nucleotide antagonist selective for P2X3 and
P2X2/3 receptors, attenuated the antinociceptive effect produced by i.c.v. administered α,β-
methylene-ATP (10 nmol), the P2X receptor agonist, in rats. Similarly, the abolishment of the P2X3
receptor mRNA in the brainstem by repeated i.c.v. pretreatments with antisense
oligodeoxynucleotide for P2X3  gene once a day for 5 consecutive days diminished the
antinociceptive effect of α,β-methylene-ATP. Furthermore, i.c.v. administration of A-317491 (1 and
10 nmol) significantly enhanced the inflammatory nociceptive behaviors induced by the intraplantar
injection of formalin and intraperitoneal injection of acetic acid. Taken together, these results
suggest that supraspinal P2X3/P2X2/3 receptors play an inhibitory role in pain transmission.
Findings
Extracellular ATP has been established as a signaling mol-
ecule that mediates diverse biological effects via P2 puri-
noceptors (P2Xn and P2Yn) in both the peripheral and
central nervous systems [1,2]. A body of evidence indi-
cates that ionotropic P2X receptors are involved in both
peripheral and spinal pain transmission [3-5]. Of the
seven P2X receptors identified to date, the expression of
the P2X3 receptors appear selective for a subpopulation of
small-diameter dorsal root ganglion neurons, which are
probably associated with nociception [6-8]. In vivo stud-
ies have provided evidence that the activation of P2X
receptors, especially the P2X3 subtype and P2X2/3 heter-
omer, contributes to an acute nociceptive behavior, hyper-
algesia and allodynia [9-12]. These observations support
the idea that the P2X3 and P2X2/3 receptors play a crucial
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role in facilitating pain transmission at the peripheral and
spinal sites. On the other hand, at the supraspinal level,
we previously reported that the intracerebroventricular
(i.c.v.) administration of ATP and P2X receptor agonists
produced mechanical and thermal antinociception in
rats, suggesting that supraspinal P2X receptors play an
inhibitory role in nociceptive transmission [13-15]. How-
ever, it remains unclear what subtypes of supraspinal P2X
receptors are involved in the antinociceptive effect. In the
present study, to clarify the involvement of P2X3/P2X2/3
receptors, we investigated the effect of i.c.v. pretreatment
with A-317491, the novel non-nucleotide antagonist
selective for P2X3/P2X2/3 receptors [16,17] and down-reg-
ulation of P2X3 receptors in the brain by antisense oligo-
deoxynucleotide (A-ODN) in rats. Furthermore, to
determine the roles of the endogenous purinergic system
through supraspinal P2X3/P2X2/3 receptors in the exacer-
bated pain states, we examined the effect of A-317491
administered i.c.v. on the inflammatory nociceptive
behaviors induced by chemical agents.
Male Sprague-Dawley rats weighing 180–250 g were used.
The experiments were conducted in accordance with the
ethical guidelines of the Kyoto University animal experi-
mentation committee, and the guidelines of the Japanese
Pharmacological Society. The surgery for i.c.v. administra-
tion was conducted according to our previous report [13].
After surgery, the animals were returned to cages and
housed individually, being allowed to recover for 5 to 7
days until the experiments started. The i.c.v. injection was
carried out in a volume of 5 μl at a constant rate of 5 μl/
30 sec.
The 20-base A-ODN endcapped with phosphorothioate
linkages (Nisshinbo Inc, Japan) were designed according
to the primary sequence of the rat P2X3 receptor cDNA
(X91167) as previously described [9]. The sequence of A-
ODN was 5'-T*G*AA*GAAGTCTGATATAC*A*G-3',
while the sequence of sense oligodeoxynucleotide (S-
ODN) served as a control was 5'-C*T*GTATATCAGACT-
TCTT*C*A-3' (* as phosphorothioate). A-ODN and S-
ODN were dissolved in PBS. I.c.v. injection of PBS (5 μl),
A-ODN (1 nmol/5 μl), or S-ODN (1 nmol/5 μl) was car-
ried out once a day for 5 consecutive days, and the behav-
ioral assessment was conducted on next day of the last
injection. After the behavioral test, the brain was
removed, and the brainstem sample was dissected. Then,
the mRNA levels for P2X3 receptor and β-actin in the
brainstem were analyzed using an RT-PCR method.
The antinociceptive effect of α,β-methylene-ATP adminis-
tered i.c.v. was measured by the paw pressure test, as pre-
viously described [13,14]. Briefly, using an analgesimeter
(Ugo Basile, Milan, Italy), the cuneate piston was put on
the right hind paw and the pressure was loaded at a rate of
32 g/sec. The pressure that elicited paw withdrawal behav-
ior, was determined as the nociceptive threshold. After
several habituation procedures, α,β-methylene-ATP
(Sigma, St. Louis, MO) dissolved in PBS was administered
i.c.v. at a dose of 10 nmol, and the nociceptive threshold
was measured 5 min after the i.c.v. administration accord-
ing to our previous reports [13,14]. Nociceptive behaviors
evoked by inflammatory stimuli using formalin and acetic
acid were assessed. For the measurement of formalin-
induced nociceptive behavior, scoring of nociceptive
behavior started immediately after the intraplantar (i.pl.)
injection of 2% formalin at a volume of 100 μl into the
right hindpaw. The nociceptive behaviors were observed
for 60 min and were quantified using a rating scale
method by assigning weights to the following categories:
the injected paw was elevated, and was not in contact with
the floor (weight = 1); and the injected paw was licked,
bitten, or shaken (weight = 2). The time an animal spent
in each behavioral category was multiplied by the cate-
gory weight (1 or 2), summed, and then divided by the
total test session period (300 sec). For the measurement of
acetic acid-induced nociceptive writhing behavior, count-
ing the number of typical writhing behaviors, character-
ized by a wave of contraction of the abdominal
musculature followed by extension of the hind limbs,
started immediately after the intraperitoneal (i.p.) injec-
tion of 2% acetic acid at a volume of 1 ml. The writhing
behavior was observed for 60 min and the number of
occurrences every 5 min was evaluated.
The statistical significance was calculated using one-way
or two-way analysis of variance (ANOVA), followed by
the Bonferroni post hoc test. Differences at P < 0.05 were
considered significant.
The effect of i.c.v. pretreatment with A-317491 (Sigma) on
the antinociceptive effect produced by i.c.v. administered
α,β-methylene-ATP was examined (Fig. 1A). I.c.v. admin-
istration of α,β-methylene-ATP (10 nmol) at 15 min after
i.c.v. pretreatment with PBS produced a significant anti-
nociceptive effect, compared with the PBS-administered
group (P < 0.001). The antinociceptive effect was dose-
dependently and significantly reduced by i.c.v. pretreat-
ment with A-317491 (F5,29 = 9.43, P < 0.001). The signifi-
cant inhibitory effect of A-317491 was observed at a dose
of 1 nmol, compared with PBS-pretreated group (P  <
0.05). A-317491 (1 nmol) itself had no effect on the noci-
ceptive threshold.
In the rat i.c.v. pretreated repeatedly with PBS and P2X3 S-
ODN, the expression of P2X3 receptor mRNA in the brain-
stem was observed, while it was diminished by the
repeated i.c.v. pretreatments with P2X3 A-ODN (Fig. 1B).
In the rat pretreated with PBS and P2X3 S-ODN, i.c.v.
administration of α,β-methylene-ATP (10 nmol) pro-Molecular Pain 2006, 2:19 http://www.molecularpain.com/content/2/1/19
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duced an antinociceptive effect, and there was no differ-
ence between them. The antinociceptive effect was
significantly reduced by the repeated i.c.v. pretreatments
with P2X3 A-ODN (F2,14 = 6.61, P < 0.01), compared with
the PBS-pretreated (P < 0.05) and P2X3 S-ODN-pretreated
(P < 0.05) groups (Fig. 1C).
To clarify the roles of supraspinal P2X3/P2X2/3 receptors in
inflammatory pain, we examined the effect of the i.c.v.
administration of A-317491 on inflammatory nociceptive
behaviors induced by i.pl. formalin and i.p. acetic acid
(Fig. 2). The i.pl. injection of formalin produced charac-
teristic biphasic nociceptive behaviors. The i.c.v. adminis-
tration of A-317491 (1 and 10 nmol) 5 min before the
formalin injection significantly increased the nociceptive
behaviors (F2,168 = 6.07, P < 0.01). Similarly, the number
of acetic acid-induced writhing behaviors was signifi-
cantly increased by the i.c.v. administration of A-317491
(1 and 10 nmol) 5 min before the acetic acid injection
(F2,168 = 6.73, P < 0.01).
The present study provides evidence that P2X3 and/or
P2X2/3  receptors are responsible for supraspinal P2X
receptor-mediated antinociception. A-317491, a selective
antagonist for P2X3 and P2X2/3 receptors, produces anti-
nociception at peripheral and spinal sites in rat models of
inflammatory and neuropathic pain[16-19]. Conversely,
we found that the acute i.c.v. injection of A-317491
blocked the antinociceptive effect of α,β-methylene-ATP,
which is selective for P2X1, P2X3 and P2X2/3 receptors, sug-
gesting that the activation of supraspinal P2X3/P2X2/3
receptors exerted the antinociceptive effect [16,17]. The
P2X3 subtype expressed in the brain is primarily distrib-
uted throughout the rat hindbrain, including the nucleus
of the solitary tract, medial vestibular nucleus, medial and
lateral parabrachial nuclei, rostral ventrolateral medulla
The involvement of supraspinal P2X3/P2X2/3 receptors in the antinociception produced by i.c.v. administration of α,β-methyl- ene-ATP Figure 1
The involvement of supraspinal P2X3/P2X2/3 receptors in the antinociception produced by i.c.v. administration 
of α,β-methylene-ATP. The nociceptive thresholds at 5 min after the i.c.v. administration of α,β-methylene-ATP (10 nmol) 
were compared in the paw pressure test. The nociceptive threshold of each animal before the i.c.v. administration served as 
the control value (100%), and the values are presented as the means of the % of the control ± S.E.M. (A) The effect of i.c.v. pre-
treatment with A-317491. α,β-Methylene-ATP or PBS was administered i.c.v. 15 min after i.c.v. pretreatment with A-317491 
(0.01–1 nmol) or PBS. ***P < 0.001 vs PBS-PBS group, #P < 0.05 vs PBS-α,β-methylene-ATP group (n = 5–8). (B) RT-PCR anal-
yses of the mRNA expression levels for P2X3 receptor (upper) and β-actin (bottom) in the brainstem after repeated i.c.v. pre-
treatments with PBS, P2X3 A-ODN (1 nmol), and P2X3 S-ODN (1 nmol). (C) The effects of repeated i.c.v. pretreatments with 
PBS, P2X3 A-ODN and P2X3 S-ODN on the antinociception by i.c.v. administered α,β-methylene-ATP. *P < 0.05 (n = 5–6).Molecular Pain 2006, 2:19 http://www.molecularpain.com/content/2/1/19
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The effect of i.c.v. administration of A-317491 on the inflammatory nociceptive behaviors Figure 2
The effect of i.c.v. administration of A-317491 on the inflammatory nociceptive behaviors. (A) For the measure-
ment of formalin-induced nociceptive behavior, the scoring of nociceptive behavior started immediately after the i.pl. injection 
of formalin into the right hindpaw. The nociceptive behaviors were observed for 60 min and were quantified using a rating 
scale method by assigning weights for each 5 min. (B) For the measurement of acetic acid-induced nociceptive writhing behav-
ior, counting the number of typical writhing behaviors started immediately after the i.p. injection of acetic acid. The writhing 
behavior was observed for 60 min and the number of occurrences every 5 min was evaluated. The i.c.v. administration of A-
317491 (1 and 10 nmol) or PBS was performed 5 min before the i.pl. injection of formalin or i.p. injection of acetic acid. The 
values are presented as the means ± S.E.M. *P < 0.05, ***P < 0.05 vs PBS group (n = 5–6).Molecular Pain 2006, 2:19 http://www.molecularpain.com/content/2/1/19
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and locus coeruleus (LC) [20,21], while the P2X2 subtype
is widely distributed in the brain, including the hindbrain
[22]. Therefore, it is assumed that the decreased effect of
α,β-methylene-ATP-induced antinociception by repeated
i.c.v. pretreatments with P2X3 A-ODN is attributed to the
decreased expression of P2X3 receptors in the hindbrain.
In the the nucleus of the solitary tract, the ultrastructural
study showed that P2X3-immunoreactive boutons syn-
apsed on dendrites and cell bodies, and had complex syn-
aptic interaction with other axon terminals and
vesiculated dendrites[20]. It is also described that α,β-
methylene-ATP excites the neurons arising from the hind-
brain, such as the LC [23,24]. We previously found that
the bilateral microinjection of α,β-methylene-ATP into
the LC produced robust antinociception, which was
inhibited by co-injection with the P2X receptor antagonist
PPADS[15], suggesting that the decreased level of P2X3
receptors in the LC by P2X3 A-ODN might have resulted in
the blockade of α,β-methylene-ATP-induced antinocicep-
tion.
There are several lines of evidence that endogenous ATP
appears to play a facilitatory role in pain transmission at
the peripheral and spinal levels, which is consistent with
the effect of the exogenous injection of ATP and P2X
receptor agonists. For instance, it has been reported that
the intrathecal injection of PPADS attenuated the nocice-
ptive behaviors induced by the i.pl. injection of formalin
and capsaicin [25]. The intrathecal injection of P2X3 A-
ODN also attenuated the hyperalgesia and allodynia after
the nerve injury [9-11], however, the role of endogenous
ATP in a supraspinal pain transmission has been unclear.
Our present study found that i.c.v. administration of A-
317491 deteriorated the inflammatory pain induced by
formalin and acetic acid, suggesting that the endogenous
ATP also plays an inhibitory role in pain transmission
through P2X3/P2X2/3 receptors at the supraspinal level.
The effect of A-317491 was rapidly normalized to the con-
trolled level in both formalin- and acetic acid-induced
inflammatory nociceptive behaviors. It is consistent with
our previous findings that the antinociceptive effect by
i.c.v. administered α,β-methylene-ATP was rapid and
short lasting. The rapid effect of A-317491 is not probably
due to the enzymatic degradation, as it is reported that A-
317491 induces a long-lasting effect following systemic
injection [16]. This might have resulted from the charac-
teristic of the P2X3 receptor, which is known to be rapidly
desensitized following its activation. Nevertheless, the
i.c.v. injection of A-317491 did not affect the baseline
nociceptive threshold in the paw pressure test (see Fig.
1A). These findings support the possibility that the
inflammatory pain, but not acute pain, might stimulate
the release of endogenous ATP into the extracellular space
at the supraspinal level, as well as the spinal
level[18,26,27].
Taken together, our findings suggest that the activation of
supraspinal P2X3/P2X2/3 receptors produces antinocicep-
tion. Since the effect at the supraspinal site is opposed to
that at peripheral and spinal sites, further study might be
needed to understand their role at the supraspinal site to
develop potential analgesics via these receptors. Moreo-
ver, our results indicate that endogenous ATP at the
supraspinal site plays an inhibitory role in the early stage
of inflammatory pain.
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